Related Experiment Video

Updated: May 6, 2026

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines
11:50

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Published on: September 10, 2014

13.0K

Organic Anion Transporting Polypeptide 5A1 (OATP5A1) in Small Cell Lung Cancer (SCLC) Cells: Possible Involvement in

U Olszewski-Hamilton1, M Svoboda, T Thalhammer

  • 1Ludwig Boltzmann Cluster of Translational Oncology, A-1090 Vienna, Austria.

Biomarkers in Cancer
|November 2, 2013
PubMed
Abstract

Insights

Organic anion transporting polypeptide 5A1 (OATP5A1) may contribute to small cell lung cancer (SCLC) chemoresistance by sequestering drugs within cells. Further research is needed to explore its role as a chemoresistance marker.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Oncology

Background:

  • Organic anion transporting polypeptide 5A1 (OATP5A1) is a drug transporter whose function remains largely uncharacterized.
  • Understanding OATP5A1's role is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To investigate the role of OATP5A1 in small cell lung cancer (SCLC).
  • To determine OATP5A1's potential involvement in chemoresistance.

Main Methods:

  • Real-time qPCR to assess OATP5A1 gene expression in SCLC cell lines.
  • MTT assays to evaluate chemosensitivity of OATP5A1-transfected cells to satraplatin.

Main Results:

  • OATP5A1 mRNA expression was significantly higher in drug-resistant SCLC cells.
  • HEK-293 cells transfected with SLCO5A1 exhibited increased resistance to satraplatin.
  • OATP5A1 was localized to the cytoplasmic membranes of tumor cells, including SCLC.

Conclusions:

  • OATP5A1 may contribute to SCLC chemoresistance through intracellular drug sequestration rather than uptake.
  • The relationship between OATP5A1 expression and clinical drug resistance warrants further investigation.
  • OATP5A1 could potentially serve as a marker for chemoresistance in SCLC.
Keywords:
HEK-293OATP5A1SCLCchemoresistancedrug transportsatraplatintransfection

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.2K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.6K

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
190
Carrier-Mediated Transport01:06

Carrier-Mediated Transport

Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
1.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
ABC Transporters: Exporter01:31

ABC Transporters: Exporter

ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
5.7K
Active Transport01:14

Active Transport

Active transport is a critical biological process that allows cells to move solutes against an electrochemical gradient. This process requires direct energy input and is characterized by its selectivity, saturability, and susceptibility to competitive inhibition.
Primary active transporters, like Na+, K+ and -ATPase, directly utilize ATP to move ions across the membrane. These transporters play significant roles in various physiological processes. For instance, Na+, K+ and -ATPase maintain...
2.7K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
11.9K